Loading...
Loading...
JANX| Name | Value |
|---|---|
| Revenues | 8.9M |
| Cost of Revenue | 0.5M |
| Gross Profit | 8.4M |
| Operating Expense | 22.2M |
| Operating I/L | -13.8M |
| Other Income/Expense | 7.9M |
| Interest Income | 7.9M |
| Pretax | -6.0M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -6.0M |
Janux Therapeutics, Inc. is a biopharmaceutical company specializing in developing cancer therapeutics. Their proprietary TRACTr platform technology is the foundation for their lead product candidates, which target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Additionally, the company is working on a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 to enhance T cell anti-tumor activity. With a focus on developing treatments for various cancer types, Janux Therapeutics, Inc. aims to generate revenue through the commercialization of these innovative therapeutics.
